Table 2. Treatment strategies for colorectal cancer during the COVID-19 pandemic compared to the pre-COVID-19 period

Author	Publication year	Proportion of patients treated with neoadjuvant treatment		P-value	Comment
		Pre-COVID-19	COVID-19
Forse CL [24]	2021	19% 17%	11% 13%	<0.001 0.044	Chemotherapy post-shutdown Chemoradiotherapy post-shutdown
Miyo M [25]	2022	3.7%	3.7%	1
Freund MR [26]	2022	65% TNT 15%	76% TNT 52%	0.0001
Eklöv K [21,22]	2022	3.5%	5.1%	0.0016	Chemotherapy for colon cancer
		44%	45%	NS	Chemoradiotherapy for rectal cancer
Rottoli M [27]	2022	51.9%	52.2%	NS	Rectal cancer
Chen MZ [28]	2022	13.7%	16.2%
Tarta C [29]	2022	7.2%	6.3% (2020) 9.5% (2021)	NS
Meijer J [20]	2022	37.7%	1) 10.3% 2) 19.8% 3) 34.1%	NS	Chemoradiotherapy
Ghosh S [30]	2022	52.9%*	40.4%*	0.008	*Patients who could receive surgery
Tang G [31]	2022	7.4%	11.8%	NS
Kiss BI [36]	2022	14.8%	17.6%	NS
Choi JY [13]	2021	36%	38.7%	0.039	All kinds of neoadjuvant therapy

TNT, total neoadjuvant therapy; NS, non-specific.